Dapoxetine

Dapoxetine
Clinical data
Trade namesEJ-30, Priligy, others (see below)
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral (tablets)
ATC code
Legal status
Legal status
  • BR: Class C1 (Other controlled substances)[1]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability15–76% (mean 42%), Tmax = 1–1.3 hours
Protein binding>99%
MetabolismLiver (CYP2D6, CYP3A4), kidney (FMO1)
MetabolitesDapoxetine-N-oxide, desmethyldapoxetine, didesmethyldapoxetine
Elimination half-life1.5–1.6 h
ExcretionKidneys[2]
Identifiers
  • (S)-N,N-Dimethyl-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H23NO
Molar mass305.421 g·mol−1
3D model (JSmol)
  • CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1
  • InChI=1S/C21H23NO/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21/h3-14,20H,15-16H2,1-2H3/t20-/m0/s1
  • Key:USRHYDPUVLEVMC-FQEVSTJZSA-N

Dapoxetine, marketed as Priligy, among others, is a selective serotonin reuptake inhibitor (SSRI) used for the treatment of premature ejaculation (PE) in men 18–64 years old.[3][4][5] Dapoxetine works by inhibiting the serotonin transporter, increasing serotonin's action at the postsynaptic cleft, and as a consequence promoting ejaculatory delay.[6] As a member of the selective serotonin reuptake inhibitor (SSRI) family, dapoxetine was initially created as an antidepressant. However, unlike other SSRIs, dapoxetine is absorbed and eliminated rapidly in the body. Its fast-acting property makes it suitable for the treatment of PE, but not as an antidepressant.[7]

Originally created by Eli Lilly pharmaceutical company, dapoxetine was sold to Johnson & Johnson in 2003 and submitted as a New Drug Application to the Food and Drug Administration (FDA) for the treatment of PE in 2004.[8] Dapoxetine is sold in several European and Asian countries, and in Mexico. In the US, dapoxetine has been in phase III development. In May 2012, US-based Furiex Pharmaceuticals reached an agreement with ALZA Corp and Janssen Pharmaceutica to market dapoxetine in the USA, Japan, and Canada, while selling the rights to market the drug in Europe, most of Asia, Africa, Latin America, and the Middle East to Menarini.[9]

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ "Priligy (dapoxetine) Film-coated Tablets, for Oral Use. Full Prescribing Information". Russian State Register of Medicines. (in Russian). 25 July 2013. Retrieved 11 August 2016.
  3. ^ Dresser MJ, Desai D, Gidwani S, Seftel AD, Modi NB (2006). "Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors". International Journal of Impotence Research. 18 (1): 104–110. doi:10.1038/Sj.Ijir.3901420. PMID 16307008.
  4. ^ McMahon CG (October 2012). "Dapoxetine: a new option in the medical management of premature ejaculation". Therapeutic Advances in Urology. 4 (5): 233–251. doi:10.1177/1756287212453866. PMC 3441133. PMID 23024705.
  5. ^ "Priligy is used to Treat Premature Ejaculation". deutschemedz.de (in German). 10 August 2015. Retrieved 19 November 2018.
  6. ^ "Australian Public Assessment Report for Dapoxetine" (PDF). Therapeutics Goods Administration. Australian Government. 2010.
  7. ^ Andersson KE, Mulhall JP, Wyllie MG (February 2006). "Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation". BJU International. 97 (2): 311–315. doi:10.1111/J.1464-410x.2006.05911.X. PMID 16430636. S2CID 34969671.
  8. ^ McCarty E, Dinsmore W (2012). "Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation". Core Evidence. 7: 1–14. doi:10.2147/CE.S13841. PMC 3273363. PMID 22315582.
  9. ^ "Furiex Pharma gets rights to Priligy, some of which it sells on to Menarini". The Pharma Letter. 15 May 2012. Retrieved 11 February 2020.